Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus clausii + fructooligosaccharides
- Development stage
- Unknown
- Lead developer
- Amspro Lifesciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Gutclaus FOS is an over-the-counter (OTC) synbiotic liquid oral suspension developed by Amspro Lifesciences. It combines the spore-forming probiotic bacterium *Bacillus clausii* (available in 2 Billion or 4 Billion CFU strengths) with the prebiotic fructo-oligosaccharides (FOS). This combination is designed to support healthy intestinal microflora, maintain gut microbiota balance, and promote digestive wellness. The spore-forming nature of *Bacillus clausii* ensures high stability and survival through the acidic environment of the stomach to reach the intestines active. Gutclaus FOS is indicated for the management of acute and chronic diarrhea, antibiotic-associated diarrhea, traveler's diarrhea, irritable bowel syndrome (IBS) support, constipation, bloating, and general gut microbiota restoration.
- Brand names
- Gutclaus FOS
- Other names
- Bacillus clausii + FOSBacillus clausii + fructo-oligosaccharides
02
Targets
TLR2 (Toll-like Receptor 2)Peptidoglycan lipid intermediates in Gram-positive bacteriaFructooligosaccharide-utilizing gut microbiota
Beyond the preview
Go deeper on Bacillus clausii + fructooligosaccharides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus clausii + fructooligosaccharides.